Category C Drug List Discussion Series
Navigating China’s Evolving Drug Pricing and Reimbursement Landscape
China’s first-ever national Category C Drug List, led by the NHSA, is set to reshape the country's multi-tier medical security system. At the same time, the Insurance Association of China (IAC) is spearheading efforts to develop a sector-wide commercial insurance drug catalog, gaining rapid traction. These initiatives signal a fundamental shift in healthcare financing, with commercial insurance poised to play a growing role in expanding access to high-value, innovative therapies.
Together, these developments will redefine funding pathways, pricing strategies, and market access for innovative medicines in China.
Join Our Exclusive NRDL+ Discussion Series
To stay ahead of these critical policy changes, join us for this NRDL+ special topic series on the Category C Drug List and its implications for pharmaceutical pricing, reimbursement, and market access.
What You’ll Learn
✅ The role of the Category C Drug List within China’s multi-tier medical security system
✅ Selection criteria for Category C drugs and their impact on Huiminbao’s specialty drug catalog
✅ Pricing strategies for Category C drugs and how they differ from NRDL pricing models
✅ The industry-led commercial insurance drug catalog and its relationship with the Category C Drug List
✅ How commercial insurers will engage with these frameworks and adopt pricing & reimbursement strategies
✅ Key policy hurdles and implementation challenges affecting both initiatives
✅ Strategic decision-making: NRDL, Category C, or industry-led drug catalogs—where should pharma prioritize?
Who’s Already Enrolled?
This discussion series has already attracted senior professionals from global pharma and consulting firms with responsibilities in pricing, reimbursement, and market access. Confirmed participants include:
✅ Head of International Pricing and Market Access
✅ Global Head of Pricing Implementation
✅ Head of China Pipeline and Access Strategy
✅ Head of Innovative Contracting and New Access Channels
✅ Global Value & Access Lead
✅ Access Marketing and Strategy Lead
✅ Global Director Access Strategy and Policy
✅ Vice President & Head, Life Sciences and Healthcare (Consulting)
✅ Business Development & Alliance Lead
The C-List discussion will feature three expert panels: Policy, China Commercial Payer, and Pharmaceutical Strategy.
Joining the waitlist helps us keep the sessions focused and ensures your key questions are addressed. You’ll get priority during Q&A — plus 10% off as a thank-you.
If your role aligns with these focus areas, we’d love to have you on the list.